EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors

Prajna Tripathi, Rajni Kumari, Rajiv Pathak

International Review of Cell and Molecular Biology · 2024

DOI: 10.1016/bs.ircmb.2023.11.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Review of Cell and Molecular Biology, 2024. Verfasst von Prajna Tripathi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Neoplasms, Signal Transduction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 157 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains the leading cause of global mortality, prompting a paradigm shift in its treatment and outcomes with the advent of targeted therapies. Among the most prevalent mutations in RAS-driven cancers, Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations account for approximately 86% of cases worldwide, particularly in lung, pancreatic, and colon cancers, contributing to poor prognosis and reduced overall survival. Despite numerous efforts to understand the biology of KRAS mutants and their pivotal role in cancer development, the lack of well-defined drug-binding pockets has deemed KRAS an "undruggable" therapeutic target, presenting significant challenges for researchers and clinicians alike. Through significant biochemical and technological advances, the last decade has witnessed promising breakthroughs in targeted therapies for KRAS-mutated lung, colon, and pancreatic cancers, marking a critical turning point in the field. In this chapter, we provide an overview of the characteristics of KRAS mutations across various solid tumors, highlighting ongoing cutting-edge research on the immune microenvironment, the development of KRAS-driven mice models, and the recent progress in the exploration of specific KRAS mutant-targeted therapeutic approaches. By comprehensive understanding of the intricacies of KRAS signaling in solid tumors and the latest therapeutic developments, this chapter will shed light on the potential for novel therapeutic strategies to combat KRAS-driven tumors and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)NeoplasmsSignal TransductionHumansAnimalsMutationMolecular Targeted TherapyAntineoplastic AgentsTumor Microenvironment

Stichwörter der Autor:innen

KRAS inhibitorsKRAS mutationsKRAS-driven mice modelsKRAS-mediated signaling pathwaysSolid tumorsTherapeutic strategyTumor microenvironment

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, United States.
  • Department of Cell Biology, Albert Einstein College of Medicine, New York, NY, United States. Electronic address: rajni.biochem@gmail.com.
  • Department of Genetics, Albert Einstein College of Medicine, New York, NY, United States. Electronic address: rajivpathak17@gmail.com.

Zitieren

APA

Tripathi, P., Kumari, R., & Pathak, R. (2024). Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors. International Review of Cell and Molecular Biology. https://doi.org/10.1016/bs.ircmb.2023.11.004

Vancouver

Tripathi P, Kumari R, Pathak R. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors. International Review of Cell and Molecular Biology. 2024. doi:10.1016/bs.ircmb.2023.11.004

BibTeX
@article{Tripathi2024,
  author = {Tripathi, Prajna and Kumari, Rajni and Pathak, Rajiv},
  title = {Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors},
  journal = {International Review of Cell and Molecular Biology},
  year = {2024},
  doi = {10.1016/bs.ircmb.2023.11.004}
}
Kostenlos starten →